Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LTR PharmaASX:LTP -1.02%12 Cash Ratio is 56.29 as of Dec. 2025, which is 77% above its 10-year median of 31.87. GuruFocus rates ASX:LTP with a GF Score™ of 12/100. Among 1,385 Biotechnology companies, LTR Pharma ranks better than 99.06% on this metric.
LTR Pharma has a Cash Ratio of 56.29. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for LTR Pharma's Cash Ratio or its related term are showing as below:
ASX:LTP'
s Cash Ratio Range Over the Past 10 Years
Min: 0.31 Med: 31.87 Max: 340.24
Current: 56.29
During the past 5 years, LTR Pharma's highest Cash Ratio was 340.24. The lowest was 0.31. And the median was 31.87.
ASX:LTP's Cash Ratio is ranked better than 99.06% of 1385
companies
in the Biotechnology industry
Industry Median: 2.93
vs ASX:LTP: 56.29
LTR Pharma (ASX:LTP) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
LTR Pharma Cash Ratio Related Terms
LTR Pharma Cash Ratio Historical Data
* Premium members only.
The historical data trend for LTR Pharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:LTP vs VRTX, REGN, ALNY: Cash Ratio Comparison
For the Biotechnology subindustry, LTR Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where LTR Pharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTR Pharma (ASX:LTP) has a Cash Ratio of 56.29 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on LTR Pharma and its competitors. This is 77% above median its historical median of 31.87. Over the past decade, LTR Pharma's Cash Ratio has ranged from 0.31 to 340.24. According to the industry distribution chart, LTR Pharma ranks #13 out of 1385 companies in the Biotechnology industry, placing it in the top 0.90000000000001%.
Is LTR Pharma's Cash Ratio too high?
LTR Pharma's current Cash Ratio of 56.29 is 77% above median its 10-year median of 31.87. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 340.24. The Biotechnology industry median Cash Ratio is 2.93. LTR Pharma's value of 56.29 is 1821.2% above this industry median. Based on the distribution chart, LTR Pharma ranks #13 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, LTR Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #13 out of 1385 companies for Cash Ratio. This places LTR Pharma in the top 1% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. LTR Pharma's value of 56.29 is 1821.2% above this benchmark. Historically, LTR Pharma's own Cash Ratio has ranged from 0.31 to 340.24 over the past decade. While the company's 10-year median is 31.87 vs. the industry median of 2.93, LTR Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LTR Pharma's current Cash Ratio of 56.29 is 1821.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on LTR Pharma and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LTR Pharma's current Cash Ratio is 56.29, which is 77% above median its own 10-year median of 31.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Cash Ratio of 56.29. The current Cash Ratio is 56.29, which is 77% above median its 10-year median of 31.87 and 1821.2% above the Biotechnology industry median of 2.93. LTR Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Cash Ratio is 56.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
12GF Score
Get the complete analysis for ASX:LTP
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 
